-
1
-
-
0029976873
-
Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis
-
Issa J, Vertino PM, Boehm CD, et al: Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 93: 11757-11762, 1996.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 11757-11762
-
-
Issa, J.1
Vertino, P.M.2
Boehm, C.D.3
-
2
-
-
0036387011
-
DNA methylation changes in leukaemia
-
Melki JR and Clark SJ: DNA methylation changes in leukaemia. Semin Cancer Biol 12: 347-357, 2002.
-
(2002)
Semin Cancer Biol
, vol.12
, pp. 347-357
-
-
Melki, J.R.1
Clark, S.J.2
-
3
-
-
0035510088
-
Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer
-
Takai D, Gonzales FA, Tsai YC, et al: Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet 10: 2619-2626, 2001.
-
(2001)
Hum Mol Genet
, vol.10
, pp. 2619-2626
-
-
Takai, D.1
Gonzales, F.A.2
Tsai, Y.C.3
-
4
-
-
62849104641
-
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
-
International Vidaza High-Risk MDS Survival Study Group
-
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232, 2009.
-
(2009)
Lancet Oncol
, vol.10
, pp. 223-232
-
-
Fenaux, P.1
Mufti, G.J.2
Hellstrom-Lindberg, E.3
-
5
-
-
68949145132
-
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial
-
Steensma DP, Baer MR, Slack JL, et al: Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27: 3842-3848, 2009.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3842-3848
-
-
Steensma, D.P.1
Baer, M.R.2
Slack, J.L.3
-
6
-
-
68049120458
-
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes
-
Voso MT, Santini V, Finelli C, et al: Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 15: 5002-5007, 2009.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5002-5007
-
-
Voso, M.T.1
Santini, V.2
Finelli, C.3
-
7
-
-
0029011539
-
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
-
Merlo A, Herman JG, Mao L, et al: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
-
(1995)
Nat Med
, vol.1
, pp. 686-692
-
-
Merlo, A.1
Herman, J.G.2
Mao, L.3
-
8
-
-
0030046322
-
Hypermeth-ylation-associated inactivation indicates a tumor suppressor role for p15INK4B
-
Herman JG, Jen J, Merlo A and Baylin SB: Hypermeth-ylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56: 722-727, 1996.
-
(1996)
Cancer Res
, vol.56
, pp. 722-727
-
-
Herman, J.G.1
Jen, J.2
Merlo, A.3
Baylin, S.B.4
-
9
-
-
0031731906
-
Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells
-
Côté S, Sinnett D and Momparler RL: Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs 9: 743-750, 1998.
-
(1998)
Anticancer Drugs
, vol.9
, pp. 743-750
-
-
Côté, S.1
Sinnett, D.2
Momparler, R.L.3
-
10
-
-
0001679798
-
Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid
-
Breitman TR, Selonick SE and Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77: 2936-2940, 1980.
-
(1980)
Proc Natl Acad Sci USA
, vol.77
, pp. 2936-2940
-
-
Breitman, T.R.1
Selonick, S.E.2
Collins, S.J.3
-
11
-
-
0019310229
-
Induction of differentiation of cultured human promyelocytic leukemia cells by retinoids
-
Honma Y, Takenaga K, Kasukabe T and Hozumi M: Induction of differentiation of cultured human promyelocytic leukemia cells by retinoids. Biochem Biophys Res Commun 95: 507-512, 1980.
-
(1980)
Biochem Biophys Res Commun
, vol.95
, pp. 507-512
-
-
Honma, Y.1
Takenaga, K.2
Kasukabe, T.3
Hozumi, M.4
-
12
-
-
0022404250
-
Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine
-
Momparler RL, Bouchard J and Samson J: Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leuk Res 9: 1361-1366, 1985.
-
(1985)
Leuk Res
, vol.9
, pp. 1361-1366
-
-
Momparler, R.L.1
Bouchard, J.2
Samson, J.3
-
13
-
-
27744545241
-
5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells
-
Liu Z, Zhang L, Ding F, et al: 5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. Cancer Lett 230: 271-283, 2005.
-
(2005)
Cancer Lett
, vol.230
, pp. 271-283
-
-
Liu, Z.1
Zhang, L.2
Ding, F.3
-
14
-
-
56349137374
-
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'treatment
-
Miasaki FY, Vivaldi A, Ciampi R, et al: Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'treatment. J Endocrinol Invest 31: 724-730, 2008.
-
(2008)
J Endocrinol Invest
, vol.31
, pp. 724-730
-
-
Miasaki, F.Y.1
Vivaldi, A.2
Ciampi, R.3
-
15
-
-
84859817127
-
The differentiating and apoptotic effects of 2-aza-5'-deoxycytidine are dependent on the PU.1 expression level in PU.1-transgenic K562 cells
-
Aoyama S, Nakano H, Danbara M, et al: The differentiating and apoptotic effects of 2-aza-5'-deoxycytidine are dependent on the PU.1 expression level in PU.1-transgenic K562 cells. Biochem Biophys Res Commun 420: 775-781, 2012.
-
(2012)
Biochem Biophys Res Commun
, vol.420
, pp. 775-781
-
-
Aoyama, S.1
Nakano, H.2
Danbara, M.3
-
16
-
-
0031025368
-
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
-
Herman JG, Civin CI, Issa JP, et al: Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837-841, 1997.
-
(1997)
Cancer Res
, vol.57
, pp. 837-841
-
-
Herman, J.G.1
Civin, C.I.2
Issa, J.P.3
-
17
-
-
80053122382
-
Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma
-
Uenogawa K, Hatta Y, Arima N, et al: Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma. Int J Mol Med 28: 835-839, 2011.
-
(2011)
Int J Mol Med
, vol.28
, pp. 835-839
-
-
Uenogawa, K.1
Hatta, Y.2
Arima, N.3
|